### NATIONAL INSTITUTE FOR HEALTH AND CARE **EXCELLENCE**

### HEALTH TECHNOLOGY APPRAISAL PROGRAMME

## **Equality impact assessment – Guidance development**

# STA Cemiplimab for treating advanced cutaneous squamous cell carcinoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

### Final appraisal determination

(when no ACD was issued)

Have the potential equality issues identified during the scoping 1. process been addressed by the committee, and, if so, how?

No potential equality issues were raised during the scoping process for the original appraisal (TA592)

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No potential equality issues have been raised in the submissions, expert statements or academic report

Have any other potential equality issues been identified by the 3. committee, and, if so, how has the committee addressed these?

No potential equality issues have been identified by the committee

cutaneous squamous cell carcinoma

Issue date: May 2022

4.	Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No	
5.	Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No	
6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable	
7.	Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Not applicable	
Approved by Associate Director (name):Janet Robertson  Date: 27 June 2022	

Technology appraisals: Guidance development
Equality impact assessment for the single technology appraisal of cemiplimab for treating advanced cutaneous squamous cell carcinoma 2 of Issue date: May 2022